vimarsana.com
  1. Home
  2. Live Updates
  3. Sys Completes Enrollment - Breaking News

Sys Completes Enrollment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023. | April 4, 2023

United statesItaly generalJulia neugebauerTim demuthEamonn nolanThomas biegiAmerican society of hematologyGerman lymphoma associationDrug administrationConstellation pharmaceuticals incXencor incUs oncology networkExchange commissionSys completes enrollmentTopline results expectedChief research

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topli

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa.

United statesItaly generalJulia neugebauerThomas biegiEamonn nolanTim demuthUs oncology networkDrug administrationDistribution servicesGerman lymphoma associationXencor incExchange commissionAmerican society of hematologyConstellation pharmaceuticals incSys completes enrollmentTopline results expected

EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible .

United statesItaly generalJulia neugebauerEamonn nolanTim demuthThomas biegiDistribution servicesTradegate exchangeNews serviceConstellation pharmaceuticals incAmerican society of hematologyXencor incUs oncology networkExchange commissionDrug administrationGerman lymphoma association

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.